![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 29, 22512-22519, July 21, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, February 29, 2000, and in revised form, April 20, 2000
The scavenger receptor class B type I (SR-BI)
mediates the selective transport of lipids from high density
lipoprotein to cells and plays an important role in the reverse uptake
of cholesterol to the liver and in the delivery of substrates for
steroidogenesis in steroidogenic organs. We report here on the
isolation and characterization of the upstream promoter region of the
rat SR-BI gene. The transcription start site for rat SR-BI was mapped,
and DNA sequence analysis revealed the presence of binding sites for
the Sp1 family in the proximal 5'-flanking region. Analysis of deletion
mutants with different 5' lengths revealed that the region between
Steroidogenic tissue cells require cholesterol to support the
synthesis of steroid hormones. Cholesterol, for steroidogenesis purposes, is preferentially supplied from circulating lipoproteins. Both low density lipoproteins
(LDL)1 and high density
lipoproteins (HDL) are capable of delivering cholesterol to support
steroidogenesis, and the relative contributions of these two
lipoproteins differ among species. HDL is the major source of
cholesterol for steroidogenesis in rodents, whereas the well known LDL
receptor pathway is generally believed to be important in humans. The
cellular metabolism of LDL particles occurs primarily via the LDL
receptor, as well as other members of the LDL receptor family (1-3),
which process LDL via endocytic uptake and lysosomal degradation (1,
2). It is also noteworthy that cholesterol uptake from HDL is
considered to be selective in that the uptake of cholesterol ester is
independent of HDL internalization (4, 5). Krieger and co-workers (6)
demonstrated that the scavenger receptor class B type I (SR-BI) is the
protein that mediates the selective uptake of lipids from HDL. SR-BI is a member of the CD36 family (7) and was found to bind a broad spectrum
of ligands, including both modified and native lipoproteins, as well as
anionic phospholipids (8). The binding of HDL to SR-BI has been shown
to be mediated by the major apolipoproteins, apoA-I, apoA-II, and
apoC-III (9). It has been shown that the selective uptake of HDL
cholesterol ester is solely dependent on the expression of SR-BI (10).
SR-BI is expressed in the steroidogenic organs and liver, which all
display a selective uptake of HDL cholesterol ester (6, 11, 12). SR-BI
expression is coordinately regulated with the steroidogenesis by
adrenocorticotropic hormone (13). Studies on homozygous null SR-BI
knockout mice showed that SR-BI is also required for maintaining normal
development of the oocyte and for female fertility (14), suggesting
that SR-BI plays a critical role in female reproduction. In addition, we and other investigators have shown that the expression of SR-BI mRNA in the immature rat ovary is rapidly induced in the theca interna cells by pregnant mare serum gonadotropin (PMSG) or human chorionic gonadotropin and that expression was also observed in the
corpus luteum of the adult rat ovary (11, 15). These observations support the conclusion that SR-BI serves as a selective mediator of
cholesterol uptake for steroid hormone synthesis and plays an important
role in female reproduction.
The regulation of the tissue-specific expression of SR-BI as well as
the mechanism by which tropic hormones up-regulate this expression
remains largely unknown. In this study, in order to elucidate the
molecular mechanism of transcriptional regulation of SR-BI gene, we
isolated and characterized the promoter region of the rat SR-BI gene.
Our results indicate that the region from Materials--
The DNA walking kit and the GC-melt were
purchased from CLONTECH (Palo Alto, CA). The dual
luciferase reporter assay system, the pGEM-T Easy vector, the Sp1
oligonucleotide, and the pGL3-Basic and pRL-SV vectors were purchased
from Promega (Madison, WI). The cytomegalovirus (CMV)
promoter/enhancer-directed expression vector, pcDNA3, was purchased
from Invitrogen (Carlsbad, CA). The QIAGEN plasmid kit was purchased
from QIAGEN (Hilden, Germany). Fugene-6 was obtained from Roche
Molecular Biochemicals, and the dRhodamine Terminator Cycle Sequencing
FS Ready Reaction Kit was purchased from Applied Biosystems.
[ Isolation and Characterization of 5'-Upstream of Rat SR-BI
Gene--
The DNA walking kit (CLONTECH) was used
for the isolation of the 5'-upstream DNA fragment of the rat SR-BI
gene. Briefly, samples of rat genomic DNA were separately digested with
five different restriction enzymes, which recognize six base pairs and
produce blunt ends. The digested DNA fragments were then separately adapter-ligated to produce five sets of DNA fragments with adapters at
their ends. Each set of DNA fragments was amplified using an adapter-specific 5'-primer (GTAATACGACTCACTATAGGGC) and a rat SR-BI
gene-specific 3'-primer (ACGGAGGCCACAGAGATGACAGAAA). Second PCR
reaction was done using nested primers (the 5'-primer,
ACTATAGGGCACGCGTGGT; and the 3'-primer,
AGCAGCAAGGTGTGTGCCTGACAGT). In order to effectively amplify the
GC-rich sequences in the upstream region of the rat SR-BI gene, GC-melt
(CLONTECH) was added to the PCR reaction mixture. The PCR products from each set were analyzed on a 1% agarose gel. Two
different sets showed major PCR products corresponding to 2.3 and 0.8 kilobase pairs, respectively. These products were cloned into the
pGEM-T Easy vector (Promega). The nucleotide sequences of two
independent clones from each PCR product were determined from both ends
by the dye terminator cycle sequencing method using an automated DNA
sequencer (Perkin-Elmer model 377).
Primer Extension Analysis--
An oligonucleotide with a
sequence in exon 1 (5'-ACGGAGGCCACAGAGATGACAGAAA) was used as a primer
for the extension reaction. The primer was end-labeled with T4
polynucleotide kinase and [
The 32P-labeled primer (lane 1,
100,000 cpm; lane 2, 20,000 cpm; lane
3, 50,000 cpm; lane 4, 100,000 cpm)
was mixed with (lanes 2-4) or without
(lane 1) 15 µg of total RNA in 20 µl of
hybridization buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 250 mM KCl) and denatured at 65 °C
for 1 h, after which the mixture was slowly cooled to room
temperature. Similarly 15 µg of yeast tRNA (lane
5), 15 µg of total RNA from rat lung (lane
6), or 15 µg of total RNA from rat adrenal gland
(lane 7) were mixed with the
32P-labeled primer (200,000 cpm), and further reactions
were performed. After the addition of 80 µl of reverse transcription
reaction mixture (25 mM Tris-HCl, pH 8.0, 90 mM
KCl, 12 mM MgCl2, 12 mM dithiothreitol, 0.6 mM each dNTP, 0.2 mM
spermidine, and 400 units of Superscript II reverse transcriptase), the
reaction was continued at 37 °C for 1 h. The extended
transcripts were recovered after RNA digestion with RNase A by phenol
extraction and ethanol precipitation, and were resolved on an 8%
denaturing polyacrylamide gel. M13mp18 DNA ladders were
co-electrophoresed in adjacent lanes as size markers, and the resulting
gel was then dried and autoradiographed.
Plasmids--
Rat SR-BI promoters containing various 5' ends
were generated by PCR using the longest rat SR-BI promoter (2.3 kilobase pairs in size) as a template. Primers used for PCR are shown
in Table I. Promoter DNA fragments containing substituted nucleotide
sequences, namely mut 1, mut 2, mut 3, mut 12, and mut 13, were also
generated by PCR using primers with the indicated nucleotide
substitutions (Table I). All of the
luciferase constructs contain pGL3-Basic Vector, which lacks both
elements of the eukaryotic promoter and enhancer sequences, and mutant
DNA fragments, which contain the same SR-BI promoter and enhancer
region (
A rat adrenal-4-binding protein/steroidogenic factor 1 (SF-1) cDNA
containing entire coding region was generated by reverse transcription-PCR and subcloned into the expression vector, pcDNA3. A DNA fragment containing the promoter region of the rat steroidogenic acute regulatory protein (StAR) gene ( Oligonucleotides--
Oligonucleotides used for EMSA studies are
listed in Table II. These oligonucleotides were annealed with their
complementary oligonucleotides to produce double-stranded DNA.
Cell Culture, Transient Transfection, and Luciferase
Assay--
MA-10 cells, originated from a mouse Leydig cell tumor,
were maintained in Waymouth medium supplemented with 15% horse serum and antibiotics. HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and
antibiotics. Cells were dispensed into 24-well plates and cultured
until reaching 70% confluence. DNA samples which contained each
reporter plasmid and pRL Renilla luciferase control vector
(for normalization) with or without an expression plasmid
(SF-1pcDNA3, pCMV-Sp1, or pCMV-Sp3) were mixed with 1.5 µl of
FuGENE 6 (Roche), and the resulting mixture was added to the cells. The
total amount of DNA (µg) was adjusted by adding the pcDNA3
plasmid if any. Cells were harvested 48 h later, and luciferase
activity was determined using a Dual Luciferase Reporter Assay
System. Measurements were made using a Lumat LB9501 luminometer
(Berthold) in a single tube, with the first assay from firefly
luciferase followed by the Renilla luciferase assay. Firefly
luciferase activities (relative light units) were normalized by
Renilla luciferase activities.
Schneider line 2 (SL2) cells, a Drosophila cell line, were a
generous gift from Dr. Noguchi (Nagoya University, Nagoya, Japan). SL2
cells were grown in Schneider's medium supplemented with 10% fetal
bovine serum at 25 °C. DNA transfection to SL2 cells was carried out
by a calcium-phosphate method (19). Cells were plated at 1 × 106 cells/60-mm dish on day 0. On day 1, the cells were
transfected with 2 µg of luciferase reporter plasmid and indicated
amount of pPac-Sp1 or pPac-USp3 expression plasmid. Total DNA amount was adjusted by the addition of the pPac plasmid. The culture medium
was not changed before or after the addition of DNA. Cells were
harvested 48 h after the transfection, and cell lysates were assayed. Protein concentrations were determined according to the method
reported by Bradford (20) using the Bio-Rad protein assay reagents.
Bovine Isolation of Nuclei and Preparation of Nuclear Extract from MA-10
Cells--
Nuclei from MA-10 cells were prepared by the method of
Hagenbuchle and Wellauer (21) with minor modifications (22). All operations were carried out at 4 °C. MA-10 cells were homogenized in
a glass Dounce homogenizer in 5 volumes of buffer A (15 mM Hepes/KOH, pH 7.8, 60 mM KCl, 15 mM NaCl, 14 mM 2-mercaptoethanol, 0.15 mM spermine, 0.5 mM spermidine, 1 mM phenylmethylsulfonyl fluoride, and 0.2% Nonidet P40) containing 0.3 M sucrose.
The homogenate was layered on top of a cushion of 0.9 M
sucrose in buffer A and centrifuged at 2,500 × g for
10 min at 4 °C. The precipitated crude nuclei were resuspended in
buffer A containing 0.9 M sucrose and re-centrifuged. The
resulting pellet was resuspended in buffer A and centrifuged again at
2,500 × g for 10 min at 4 °C. The preparation of a
nuclear extract from a sample of pure nuclei was performed by the
method of Frain et al. with minor modifications. Briefly,
pure nuclei were resuspended in 5 volumes of buffer B (20 mM Hepes/NaOH, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride, and 10% glycerol) using a Dounce homogenizer, gently stirred
with a magnetic stirrer on ice for 45 min, and then centrifuged at 27,000 × g for 15 min. 0.01 volume of 10% Nonidet P40
was added to the supernatant, and the resulting suspension was gently
stirred on ice for 10 min and centrifuged at 27,000 × g for 5 min. The clear supernatant was dialyzed twice for
2 h against 50 volumes of buffer C (25 mM Tris/HCl, pH
8.0, 1 mM EDTA, 5 mM MgCl2, 0.1% Nonidet P-40, 1 mM dithiothreitol, and 10% glycerol)
containing 0.1 M KCl. The dialysate was centrifuged at
27,000 × g for 10 min at 4 °C to remove the
insoluble materials. Protein concentrations of the supernatant were
determined using the protein assay kit.
EMSA--
A nuclear extract (2.5 µg of proteins) was incubated
for 30 min with a 32P-labeled oligonucleotide (0.1 ng) and
1 µg of poly(dA-dT) in buffer C. In the competition experiments, a
200-fold molar excess of unlabeled competitor DNAs was added. A
supershift assay was carried out by preincubating the nuclear extracts
for 30 min with 1 µl of anti-Sp1 or anti-Sp3 antibodies. After the
binding reaction, the mixture was subject to PAGE (4% gel) in 45 mM Tris, 45 mM boric acid, 1 mM
EDTA at 200 V for 60 min and, following this, the gel was dried and
exposed to Kodak XAR film.
The 5' upstream region of the rat SR-BI gene was isolated using
the PCR-based DNA walking kit. Two PCR products (2.3 and 0.8 kilobase
pairs in size) were obtained from rat genomic libraries. Since the 5'
upstream region of the rat SR-BI gene is quite rich in GC, the GC-melt
kit was used to isolate the PCR products. In the absence of the
GC-melt, no PCR product was amplified by the DNA walking kit procedure.
The two DNA fragments were ligated into the pGEM-T Easy vector for
sequencing. Sequence analysis revealed that the two DNA fragments
differ only in their length at their 5'-regions. Fig.
1 shows the nucleotide sequence of the longer fragment. To determine the transcription start site for rat
SR-BI gene, a primer extension analysis was performed. An end-labeled
oligonucleotide primer, which is complementary to the 5'-untranslated
region of rat SR-BI mRNA, was used. Total RNA from immature rat
ovaries primed with 30 IU of PMSG for 6 h was used for the
extension reaction. A radiolabeled product was detected in samples
containing the RNA from the ovary and adrenal gland, where strong SR-BI
gene expression is observed, whereas no product was detected in samples
containing yeast tRNA or RNA from lung. The primer produced an
extension fragment, which contained 67 nucleotides (Fig.
2), indicating that the start site for
the transcription is located 128 bp upstream of the translation start
site (Fig. 1).
The sequence contains a number of putative transcription factor binding
sites. A potential TATA boxlike sequence was present about 30 bp
upstream from the transcription start site. The sequence is
particularly rich in guanine and cytosine residues and contains four
Sp1/Sp3 transcription factor consensus elements.
As a first step in determining the sequence required for
transcriptional activity of the rat SR-BI gene, a series of plasmids was prepared. These plasmids contained upstream fragments of
Transcriptional Regulation of Rat Scavenger Receptor Class B
Type I Gene*
,
,
¶
Department of Biochemistry, Fukui Medical
University, Shimoaizuki, Matsuoka, Fukui 910-1193 and the
§ Department of Obstetrics and Gynecology, Gunma University
School of Medicine, Maebashi, Gunma 371-8511, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
121 and
90 base pairs from the transcription start site is
essential for the efficient transcription of SR-BI. Both Sp1 and Sp3
bind to three GC boxes in the region (
141 to
1 base pairs) in a
sequence-specific manner. Mutations in any of the GC boxes decreased
efficient transcription from this promoter in MA-10 mouse Leydig tumor
cells. The overexpression of Sp1 or Sp3 protein enhanced the rat SR-BI
promoter activity. These results indicate that Sp1 family members of
transcription factors are essential for transcription of the rat SR-BI gene.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
121 to
90 upstream of the
SR-BI transcription start site is essential for the expression of the
rat SR-BI gene. The DNA sequences within the region to which protein
binding occurs were characterized and shown to have homology to the
consensus binding site for the three-zinc finger transcription factor,
Sp1, which binds to the GC-rich sequences (16). We demonstrate that Sp1
binds to three sites within the region of the rat SR-BI gene promoter.
Mutations in these sequences abrogate Sp1 binding and blunt the
activity of the SR-BI promoter. These data suggest that Sp1 plays an
important role in conferring promoter activity of the rat SR-BI gene.
Sp1 is ubiquitously expressed and required for the constitutive and inducible expression of a variety of genes. To date, three Sp1-related proteins have been identified, namely Sp2, Sp3, and Sp4. Among these,
Sp1 and Sp3 are thought to be important for the expression of various
genes in mammalian tissues (17). In this study, relationships of Sp3 as
well as Sp1 for the gene expression of SR-BI were also examined.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP (111TBq/mmol) was from NEN Life Science
Products. The anti-Sp1 (SC-420X) and the anti-Sp3 (SC-644X) antibodies
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
The QuickChange site-directed mutagenesis kit was from Stratagene (La
Jolla, CA). The Superscript II reverse transcriptase was from Life
Technologies, Inc. The protein assay kit was purchased from Bio-Rad.
PMSG was a product from Teikokuzouki, Inc. (Tokyo, Japan).
-32P]ATP at 37 °C for 30 min. Total RNA was prepared by the acid guanidium thiocyanate
extraction method (18) from immature rat ovaries primed with 30 IU of
PMSG for 6 h or from immature rat lung and adrenal gland.
141/+13) with different point mutations. The promoter DNA
fragments of mut 23 and mut 123 were generated by means of the
QuickChange site-directed mutagenesis kit. The numbering of the
nucleotides is relative to the transcription start site (+1). All the
5' primers contained the NheI site. A HindIII
site was involved in the 3'-primer for mut 2 and mut 3. As a result,
the PCR products of mut 2 and mut 3 were digested with
NheI/HindIII and subcloned into
NheI/HindIII sites of the pGL3-Basic Vector. For
the generation of luciferase constructs of mut 1, mut 12, and mut 13, on the other hand,
40/+13 SR-BI promoter region was initially removed
from the PCR products of mut 1, mut 12, and mut 13 by using a
SmaI site at
40. Then the digested products were ligated
with the pGL3-Basic Vector containing
40/+13 SR-BI promoter region,
resulting in the luciferase constructs, which contain the same SR-BI
enhancer and promoter regions as those of wild type, mut 2, or mut 3 luciferase constructs. The vector which contains the
40/+13 SR-BI
promoter region was generated by removing the
NheI/SmaI fragment from the wild type reporter containing
141/+13 SR-BI promoter region. All reporter plasmids were
authenticated by DNA sequencing. pCMV-Sp1, pCMV-Sp3, pPac-Sp1, and
pPac-USp3 vectors were generous gifts from Dr. Guntram Suske (Philipps-Universitaet Marburg, Marburg, Germany).
Nucleotide sequences of oligonucleotides used for PCR
1597/+46) was isolated by means
of the DNA walking kit (CLONTECH) and was subcloned
into pGL3-Basic Vector.
-globulin was used as a standard. Firefly luciferase activity
was measured with cell lysates containing equal amount of proteins.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (110K):
[in a new window]
Fig. 1.
Nucleotide sequence of 5'-flanking regions of
rat SR-BI. The transcription start site is indicated by an
arrow, a potential TATA box is underlined, and
potential GC boxes are enclosed by boxes.

View larger version (42K):
[in a new window]
Fig. 2.
Determination of the transcription start site
by primer extension analysis. 32P-Labeled primer
(lane 1, 100,000 cpm; lane
2, 20,000 cpm; lane 3, 50,000 cpm;
lane 4, 100,000 cpm) was mixed with
(lanes 2-4) or without (lane
1) 15 µg of total RNA prepared from immature rat ovaries
primed with PMSG. Lanes 5-7 contain the
32P-labeled primer (200,000 cpm) and 15 µg of yeast tRNA
(lane 5), 15 µg of total RNA from lung
(lane 6), and 15 µg of total RNA from adrenal
gland, respectively. The primer was extended with 400 units of reverse
transcriptase at 37 °C for 1 h. Extension products were
resolved on an 8% denaturing polyacrylamide gel. A dideoxy sequence
ladder is shown next to the extension products for size determination.
The number corresponds to the number of bases 5' of the
start of translation.
2170/+13(SR2170luc),
978/+13(SR978luc),
416/+13(SR416luc),
141/+13(SR141luc),
121/+13(SR121luc),
90/+13 (SR90luc),
40/+13
(SR40luc), respectively, which were placed upstream of the luciferase
reporter gene. The plasmids were transiently transfected into MA-10
cells, and the reporter activity determined. As shown in Fig.
3, SR2170luc has an activity about 50%
lower than SR978luc, SR416luc, SR141luc, and SR121luc constructs. This
may correspond to the presence of a silencer activity between
2170
and
978. Fig. 3 also shows that deletion of
121 to
90
dramatically decreased activity (less than 2% of the activity of the
wild type promoter, SR141luc). These data strongly suggest that the
region between
121 and
90 is important for the positive regulation
of rat SR-BI expression. This region contains two GC boxes, which are
compatible with putative Sp1 binding sites (GC box 2 and GC box 3).
Removal of the most proximal Sp1 site (GC box 1), between
90 and
40, essentially abolished promoter activity. Although the 5'-deletion
analysis suggests that Sp1 family transcription factors regulate SR-BI
promoter activity, this does not directly address the roles of the GC
boxes relative to SR-BI expression. As a result, we individually and combinatorially mutated the three GC boxes within the SR141luc reporter
construct.

View larger version (18K):
[in a new window]
Fig. 3.
Deletion analysis of rat SR-BI promoter.
Constructs used in this experiment are schematically drawn and were
prepared as described under "Experimental Procedures." MA-10 cells
were transiently transfected with 0.1 µg of reporter plasmids along
with 0.001 µg of pRL Renilla luciferase control vector.
pRL Renilla luciferase activity was also measured for
normalization. The activity of the construct SR2170luc was arbitrarily
defined as 1. Each value represents the mean and standard error of four
independent transfection experiments.
As shown in Fig. 4, mutations in any one
of the GC boxes resulted in only 20-35% of the activity relative to
the wild type promoter SR141luc. mut 13 (mutated in both GC boxes 1 and
3) caused a further decrease in activity to 8% of the control value.
mut 12 (mutated in both GC boxes 1 and 2) and mut 23 (mutated in both GC boxes 2 and 3) did not result in any further decrease compared with
those of mut 1 (mutated in GC box 1) and mut 3 (mutated in GC box 3),
respectively. These results suggest that each GC box is required for a
high level of SR-BI expression.
|
To determine if nuclear proteins are capable of specifically binding to
these sites, EMSAs were performed using nuclear extracts from MA-10
cells. For these experiments, radiolabeled oligonucleotides corresponding to
121/
86 (containing GC boxes 2 and 3) and
61/
40 (containing GC box 1) of the rat SR-BI promoter were used with or
without an added 200-fold molar excess of unlabeled
121/
86 or
61/
40 oligonucleotide, or those encoding canonical Sp1-binding (23)
and NF-Y-binding (24) consensus sequences.
As shown in Fig. 5, four major complexes
were formed with the
121/
86 probe (lane 1)
and two major complexes were formed with the
61/
40 probe
(lane 9). The formation of these complexes were
prevented by the addition of an excess of the unlabeled homologous probes as well as the Sp1 consensus oligonucleotide (lanes
2 and 3 and lanes 10 and
11), but not by an unrelated probe, such as the NF-Y
consensus oligonucleotide (lanes 5 and
13). When the radiolabeled
121/
86 probe was used, an
excess of unlabeled
61/
40 oligonucleotide partially prevented the
complex formation. When the radiolabeled
61/
40 probe
(lane 4) was used, excess unlabeled
121/
86
oligonucleotide almost completely prevented complex formation (lane 12). We next examined the effects of
mutations at the two GC boxes (GC box 2 and GC box 3) where Sp1 binds.
With the use of radiolabeled
121/
86 probe, excess amounts of
neither mut 3 nor mut 23 (Table II) were
effective in preventing complex formation, whereas mut 2 was partially
effective. This suggests that the GC box 3 plays a more important role
in terms of complex formation than GC box 2. With the use of
radiolabeled
61/
40 probe, the excess unlabeled mut1 had no effect
on complex formation (lane 14).
|
|
To identify the proteins in the MA-10 nuclear extract that bind to
these positions in the native rat SR-BI promoter, EMSA supershift
experiments were performed by using the radiolabeled
121/
86 and
61/
40 oligonucleotides and antibodies that are specific for Sp1 and
Sp3 (Fig. 6). Initial complex bands with the radiolabeled
121/
86 probe were supershifted by the addition of
either the Sp1 (lane 2) or Sp3 (lane
3) antibodies, although the initial bands were still
observed faintly. The simultaneous addition of anti- Sp1 and Sp3
antibodies caused the supershift and the complete disappearance of the
initial bands (lane 4). Similar results were
obtained with the use of radiolabeled
61/
40 probe (lanes
6-8). These results indicate that Sp1 and Sp3 proteins in
the MA-10 cell nuclear extracts are actually binding to
121/
86 and
61/
40 regions of the rat SR-BI promoter.
|
We next determined whether Sp1 and Sp3 proteins are involved in SR-BI
promoter activity. MA-10 cells were transiently co-transfected with
luciferase reporter plasmids and expression vectors for Sp1 or Sp3. Two
different SR-BI promoter constructs (SR978luc and SR141luc) were used
as luciferase reporter plasmids. As shown in Fig.
7 (A and B),
co-transfection of the Sp1 expression vector caused an increase in the
SR-BI promoter activity of both SR978luc and SR141luc reporters in a
dose-dependent manner. However, co-transfection of the Sp3
expression vector failed to enhance the activity of the SR-BI promoter.
One possible explanation is that effects of transfection of the Sp3
expression vector are masked by endogenous Sp3 proteins in the MA-10
cells. Therefore, in order to confirm the effect of Sp3 on
transcriptional activity of the SR-BI gene promoter, the SL2 cell line,
which lacks endogenous Sp1 families, was employed. As shown in Fig.
8A, co-transfection of either
the Sp1 or the Sp3 expression vector caused an increase in the SR-BI promoter activity of both SR978luc and SR141luc reporters in the SL2
cells. However, the increment of the promoter activity by Sp3 was about
30% of that caused by Sp1 but statistically significant (p < 0.01, pPac versus pPac-USp3).
Furthermore, the increment of promoter activity by Sp1 was only
marginal when mut123 (mutated in all of the three GC boxes) reporter
construct was used (Fig. 8B). Similarly Sp3 was not
effective when mut123 reporter construct was used (Fig. 8B).
These results clearly indicate that Sp1 and Sp3 directly interact with
the three GC boxes within the SR141luc reporter construct and
positively regulate SR-BI promoter activity.
|
|
It has been reported that SF-1, an orphan member of the nuclear hormone
receptor gene family, binds to the human SR-BI gene promoter and is an
important regulator of SR-BI expression in steroidogenic cells, in
which SF-1 is expressed at high levels. In this study, we examined the
effects of SF-1 on the regulation of the rat SR-BI gene expression.
Regulation of rat StAR gene promoter activity by SF-1 was also examined
for the sake of comparison. StAR is the protein that delivers
cholesterol from the outer to the inner mitochondrial membrane, and
expression of this protein is positively regulated by SF-1. HeLa cells,
which express no SF-1 protein, were transiently transfected with either
SR978luc, SR141luc, rat StAR promoter, or a control vector. The cells
were co-transfected with the SF-1 expression vector, and promoter
activity was then measured 48 h after co-transfection. As shown in
Fig. 9, the co-transfection of the SF-1
expression vector did not affect promoter activity of either of the
SR-BI luciferase constructs, whereas an 8-fold up-regulation of StAR
promoter activity was observed as a results of the addition of SF-1.
This suggests that SR-BI expression in rat, unlike human, is not
influenced by SF-1.
|
| |
DISCUSSION |
|---|
|
|
|---|
We have cloned and characterized the upstream DNA fragment of the rat SR-BI gene. Only a single SR-BI transcription start site was identified in the immature rat ovary and adrenal gland using the primer extension assay. Nucleotide sequence analysis revealed that the proximal 5'-flanking region involves a GC-rich sequence. Four Sp1 binding sites are present in the GC-rich region. A similar GC-rich sequence was also found in the proximal 5'-flanking region of the human SR-BI gene. In the case of the human gene, there are five Sp1 binding sites and a single site for each SF-1 and NF-Y at the proximal region (25). Recently, the nucleotide sequence of the rat SR-BI gene has been reported by Lopez et al. (26). However, the sequence reported by Lopez et al. is different from ours in the region beyond 1517 bp upstream of the translation start site, although the reason for this discrepancy is not clear.
We have shown that Sp1 family transcription factor(s) is essential for
the rat SR-BI gene expression. To date three Sp1-related proteins have
been identified, namely Sp2, Sp3, and Sp4. Sp1 and Sp3 are thought to
be important for the expression of various genes in mammalian tissues.
In this study we have shown that both Sp1 and Sp3 are involved in
complex formation with the GC boxes in the rat SR-BI promoter. In
recent years it has been shown that Sp1 and/or Sp3 are indeed involved
in the hormone-regulated induction of a variety of genes, although
these proteins are ubiquitously expressed. We and others have shown
that rat SR-BI gene expression is positively regulated by tropic
hormone human chorionic gonadotropin in the ovary (11, 15).
Gonadotropins exert their actions by increasing intracellular cAMP
levels via the activation of adenylate cyclase. Several reports have
shown that Sp1-binding sites are required for cAMP mediated induction
of genes. For example, the genes for cholesterol side-chain cleavage
cytochrome P450 (27, 28), the rhesus growth hormone variant (29),
serum/glucocorticoid-inducible kinase (30), and the luteinizing hormone
-subunit (31) have been shown to require Sp1-binding sites for
cAMP-mediated induction. Sp1 is regulated by phosphorylation and
dephosphorylation. Cyclic AMP-dependent protein kinase also
catalyzes the phosphorylation of Sp1 and enhances its binding to the
cognate sequence. Transfection of Sp1 stimulates the
cAMP-dependent transcriptional activity of cholesterol
side-chain cleavage cytochrome P450 gene promoter in SL2 cells which
lack the endogenous Sp1 protein family (32). Similar coordinated
regulation by the Sp1 family and cAMP signal transduction pathway may
function in the expression of the rat SR-BI gene. However, the
overexpression of the cyclic AMP-dependent protein kinase
catalytic subunit in MA-10 cells could not enhance rat SR-BI promoter
activity, whereas the rat StAR gene promoter activity was shown to be
enhanced (5-fold) in a similar experiment (data not shown). Further
study is clearly needed in order to clarify the relationship between
the Sp1 family and the cAMP-dependent activation of the rat
SR-BI gene. Lopez et al. (26) reported that the sterol
regulatory element-binding protein-1a binds to GC box 3 and activates
transcription of SR-BI gene (26). However, our EMSA supershift
experiments showed that the antibodies against Sp1 and Sp3 caused
complete disappearance of the complex bands that had been initially
formed with the GC box 3 probe. At least in MA-10 cells, Sp1 and Sp3
may be the major proteins that interact with SR-BI GC box 3, although
SREBP is another member that interacts with the box.
Only a few studies have been directed at the characterization of SR-BI
gene promoters. In human, Cao et al. (25) reported that
SF-1, an orphan member of nuclear hormone receptor family, binds to the
proximal site of human SR-BI gene promoter region and that efficient
transcription from this promoter in adrenocortical Y1 cells is
dependent on the intact SF-1 site. SF-1 mRNA is constitutively expressed in adrenocortical cells, the Leydig cells in the testis, and
the thecal and corpus luteal cells in the ovary (33). SF-1 activates
the expression of a number of components of the steroidogenic complex,
including the P450 side-chain cleavage enzyme gene (34), the
17
-hydroxylase/c17-20 lyase gene (35), the aromatase cytochrome P450 gene (36-38), and StAR (39-42). The finding by Cao et
al. supports the view that SR-BI also plays an important role in
delivering lipids for steroidogenesis. However, Cao et al.
also concluded that transcription factors other than SF-1 participate
in the regulation of the human SR-BI gene expression, even in
steroidogenic tissues. In addition, SF-1 is not expressed in a number
of tissues that express SR-BI including the liver, mammary gland, and
human placenta. These facts indicate that other transcription factors must regulate SR-BI expression in these tissues.
In contrast to the human SR-BI gene, there is no SF-1 binding site consensus sequence in the 5'-upstream region proximal to the transcription start site of rat SR-BI. Instead, there is an SF-1 site (87% identity to the SF-1 site reported for the rat StAR gene) 28 bp downstream of the transcription start site. Another SF-1 consensus sequence is found at a very distal site (516 bp upstream) from the transcription start site. However, the removal of the region containing the distal SF-1 site had no effect on SR-BI promoter activity. Lopez et al. have reported, however, that the two SF-1 sites (the distal site and the downstream site in the first exon) are important for the rat SR-BI promoter activity in human HTB9 bladder carcinoma and mouse Y1 tumor cells (43). The reason for the discrepancy is presently unknown, but might be due to differences in the promoter constructs used. All promoter constructs used in this study did not contain the downstream SF-1 site, which is present in the first exon. In addition, even when the reporter construct containing the distal SF-1 site was transfected into HeLa cells, which do not express endogenous SF-1 protein, the promoter activity was not affected by the co-transfection of SF-1 expression vector. On the other hand, rat StAR promoter activity was actually enhanced by the co-transfection of SF-1 expression vector in the same culture system (Fig. 9). The findings suggest that SF-1 may not be essential for the expression of rat SR-BI gene. Unlike StAR or other steroidogenic enzymes, SR-BI is expressed in the liver, where SR-BI is believed to play a crucial role for the reverse uptake of cholesterol. Since SF-1 is not expressed in the liver, a different combination of transcription factors including the Sp1 family may function to express SR-BI gene at least in the liver.
In the present study, we demonstrated that the Sp1 family transcription
factors, rather than SF-1, are important for rat SR-BI gene expression.
However, these Sp1 family proteins are ubiquitously expressed.
Tissue-specific factors that have not yet been characterized must
participate in the regulation of SR-BI gene expression in coordination
with Sp1 family proteins. In order to define the regulation of SR-BI
gene expression, further studies will be required for characterizing
such factors.
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Dr. Mario Ascoli for providing the MA-10 cells. We also grateful to Dr. Guntram Suske for the CMV-Sp1, CMV-Sp3, pPac-Sp1, and pPac-Usp3 expression vectors. We also thank Dr. Tamio Noguchi for the generous gift of the SL2 cells.
| |
FOOTNOTES |
|---|
* This work was supported, in part, by a grant-in-aid for scientific research from the Ministry of Education, Science, Sports and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AB029825.
¶ To whom correspondence should be addressed: Dept. of Biochemistry, Fukui Medical University, Simoaizuki, Matsuoka, Fukui 910-1193, Japan. Tel.: 81-776-61-8315; Fax: 81-776-61-8102; E-mail: kmiyamot@fmsrsa.fukui-med.ac.jp.
Published, JBC Papers in Press, May 2, 2000, DOI 10.1074/jbc.M001631200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: LDL, low density lipoprotein; HDL, high density lipoprotein; SR-BI, scavenger receptor class B type I; apo, apolipoprotein; PMSG, pregnant mare serum gonadotropin; SF-1, steroidogenic factor 1; StAR, steroidogenic acute regulatory protein; bp, base pair(s); PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; mut, mutant; EMSA, electrophoretic mobility shift assay; CMV, cytomegalovirus.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Brown, M. S., and Goldstein, J. L. (1986) Science 232, 34-47 |
| 2. | Goldstein, J. L., Brown, M. S., Anderson, R. G., Russell, D. W., and Schneider, W. J. (1985) Annu. Rev. Cell Biol. 1, 1-39 |
| 3. | Krieger, M., and Herz, J. (1994) Annu. Rev. Biochem. 63, 601-637 |
| 4. | Glass, C., Pittman, R. C., Weinstein, D. B., and Steinberg, D. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 5435-5439 |
| 5. | Glass, C., Pittman, R. C., Civen, M., and Steinberg, D. (1985) J. Biol. Chem. 260, 744-750 |
| 6. | Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., and Krieger, M. (1996) Science 271, 518-520 |
| 7. | Acton, S. L., Scherer, P. E., Lodish, H. F., and Krieger, M. (1994) J. Biol. Chem. 269, 21003-21009 |
| 8. | Rigotti, A., Acton, S. L., and Krieger, M. (1995) J. Biol. Chem. 270, 16221-16224 |
| 9. | Xu, S., Laccotripe, M., Huang, X., Rigotti, A., Zannis, V. I., and Krieger, M. (1997) J. Lipid Res. 38, 1289-1298 |
| 10. | Fluiter, K., and van Berkel, T. J. (1997) Biochem. J. 326, 515-519 |
| 11. | Landschulz, K. T., Pathak, R. K., Rigotti, A., Krieger, M., and Hobbs, H. H. (1996) J. Clin. Invest. 98, 984-995 |
| 12. | Wang, N., Weng, W., Breslow, J. L., and Tall, A. R. (1996) J. Biol. Chem. 271, 21001-21004 |
| 13. | Rigotti, A., Edelman, E. R., Seifert, P., Iqbal, S. N., DeMattos, R. B., Temel, R. E., Krieger, M., and Williams, D. L. (1996) J. Biol. Chem. 271, 33545-33549 |
| 14. | Trigatti, B., Rayburn, H., Viñals, M., Braun, A., Miettinen, H., Penman, M., Hertz, M., Schrenzel, M., Amigo, L., Rigotti, A., and Krieger, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9322-9327 |
| 15. | Mizutani, T., Sonoda, Y., Minegishi, T., Wakabayashi, K., and Miyamoto, K. (1997) Biochem. Biophys. Res. Commun. 234, 499-505 |
| 16. | Lania, L., Majello, B., and De Luca, P. (1997) Int. J. Biochem. Cell Biol. 29, 1313-1323 |
| 17. | Philipsen, S., and Suske, G. (1999) Nucleic Acids Res. 27, 2991-3000 |
| 18. | Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159 |
| 19. | Di Nocera, P. P., and Dawid, I. B. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 7095-7098 |
| 20. | Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 |
| 21. | Hagenbuchle, O., Schibler, U., Petrucco, S., Van Tuyle, G. C., and Wellauer, P. K. (1985) J. Mol. Biol. 185, 285-293 |
| 22. | Yamada, K., Tanaka, T., and Noguchi, T. (1997) Biochem. J. 324, 917-925 |
| 23. | Kadonaga, J. T., Carner, K. R., Masiarz, F. R., and Tjian, R. (1987) Cell 51, 1079-1090 |
| 24. | Maity, S. N., and de Crombrugghe, B. (1998) Trends Biochem. Sci. 23, 174-178 |
| 25. | Cao, G., Garcia, C. K., Wyne, K. L., Schultz, R. A., Parker, K. L., and Hobbs, H. H. (1997) J. Biol. Chem. 272, 33068-33076 |
| 26. | Lopez, D., and McLean, M. P. (1999) Endocrinology 140, 5669-5681 |
| 27. | Venepally, P., and Waterman, M. R. (1995) J. Biol. Chem. 270, 25402-25410 |
| 28. | Liu, Z., and Simpson, E. R. (1997) Mol. Endocrinol. 11, 127-137 |
| 29. | Schanke, J. T., Durning, M., Johnson, K. J., Bennett, L. K., and Golos, T. G. (1998) Mol. Endocrinol. 12, 405-417 |
| 30. | Alliston, T. N., Maiyar, A. C., Buse, P., Firestone, G. L., and Richards, J. S. (1997) Mol. Endocrinol. 11, 1934-1949 |
| 31. | Kaiser, U. B., Sabbagh, E., Chen, M. T., Chin, W. W., and Saunders, B. D. (1998) J. Biol. Chem. 273, 12943-12951 |
| 32. | Ahlgren, R., Suske, G., Waterman, M. R., and Lund, J. (1999) J. Biol. Chem. 274, 19422-19428 |
| 33. | Morohashi, K., Honda, S., Inomata, Y., Handa, H., and Omura, T. (1992) J. Biol. Chem. 267, 17913-17919 |
| 34. | Morohashi, K., Zanger, U. M., Honda, S., Hara, M., Waterman, M. R., and Omura, T. (1993) Mol. Endocrinol. 7, 1196-1204 |
| 35. | Zhang, P., and Mellon, S. H. (1996) Mol. Endocrinol. 10, 147-158 |
| 36. | Carlone, D. L., and Richards, J. S. (1997) Mol. Endocrinol. 11, 292-304 |
| 37. | Lynch, J. P., Lala, D. S., Peluso, J. J., Luo, W., Parker, K. L., and White, B. A. (1993) Mol. Endocrinol. 7, 776-786 |
| 38. | Michael, M. D., Kilgore, M. W., Morohashi, K., and Simpson, E. R. (1995) J. Biol. Chem. 270, 13561-13566 |
| 39. | Sugawara, T., Holt, J. A., Kiriakidou, M., and Strauss, J. F., III (1996) Biochemistry 35, 9052-9059 |
| 40. | Sugawara, T., Kiriakidou, M., McAllister, J. M., Holt, J. A., Arakane, F., and Strauss, J. F., III (1997) Steroids 62, 5-9 |
| 41. | Clark, B. J., Soo, S. C., Caron, K. M., Ikeda, Y., Parker, K. L., and Stocco, D. M. (1995) Mol. Endocrinol. 9, 1346-1355 |
| 42. | Sandhoff, T. W., Hales, D. B., Hales, K. H., and McLean, M. P. (1998) Endocrinology 139, 4820-4831 |
| 43. | Lopez, D., Sandhoff, T. W., and McLean, M. P. (1999) Endocrinology 140, 3034-3044 |
This article has been cited by other articles:
![]() |
A. J. Kuhl, S. M. Ross, and K. W. Gaido CCAAT/Enhancer Binding Protein {beta}, But Not Steroidogenic Factor-1, Modulates the Phthalate-Induced Dysregulation of Rat Fetal Testicular Steroidogenesis Endocrinology, December 1, 2007; 148(12): 5851 - 5864. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yang, Z. Zhang, W. Jiang, L. Gao, G. Zhao, Z. Zheng, M. Wang, S. Si, and B. Hong Identification of Novel Human High-Density Lipoprotein Receptor Up-regulators Using a Cell-Based High-Throughput Screening Assay J Biomol Screen, March 1, 2007; 12(2): 211 - 219. [Abstract] [PDF] |
||||
![]() |
K. Yamada, H. Kawata, T. Mizutani, T. Arima, T. Yazawa, K. Matsuura, Z. Shou, T. Sekiguchi, M. Yoshino, T. Kajitani, et al. Gene Expression of Basic Helix-Loop-Helix Transcription Factor, SHARP-2, Is Regulated by Gonadotropins in the Rat Ovary and MA-10 Cells Biol Reprod, January 1, 2004; 70(1): 76 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-A. Hsu, Y.-L. Ko, S. Wu, M.-S. Teng, T.-Y. Peng, C.-F. Chen, C.-F. Chen, and Y.-S. Lee Association Between a Novel 11-Base Pair Deletion Mutation in the Promoter Region of the Scavenger Receptor Class B Type I Gene and Plasma HDL Cholesterol Levels in Taiwanese Chinese Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1869 - 1874. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yazawa, T. Mizutani, K. Yamada, H. Kawata, T. Sekiguchi, M. Yoshino, T. Kajitani, Z. Shou, and K. Miyamoto Involvement of Cyclic Adenosine 5'-Monophosphate Response Element-Binding Protein, Steroidogenic Factor 1, and Dax-1 in the Regulation of Gonadotropin-Inducible Ovarian Transcription Factor 1 Gene Expression by Follicle-Stimulating Hormone in Ovarian Granulosa Cells Endocrinology, May 1, 2003; 144(5): 1920 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sekiguchi, T. Mizutani, K. Yamada, T. Yazawa, H. Kawata, M. Yoshino, T. Kajitani, T. Kameda, T. Minegishi, and K. Miyamoto Transcriptional Regulation of the Epiregulin Gene in the Rat Ovary Endocrinology, December 1, 2002; 143(12): 4718 - 4729. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. G. Hullinger, R. L. Panek, X. Xu, and S. K. Karathanasis p21-activated Kinase-1 (PAK1) Inhibition of the Human Scavenger Receptor Class B, Type I Promoter in Macrophages Is Independent of PAK1 Kinase Activity, but Requires the GTPase-binding Domain J. Biol. Chem., December 7, 2001; 276(50): 46807 - 46814. [Abstract] [Full Text] [PDF] |
||||